Unlike other agents, it does not interfere with folate binding or transport but targets FRα‐expressing tumor cells through mechanisms like antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity [13]. The gene discussed is FOLR1; the disease is neoplasm.